BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1348403)

  • 1. Comparative effects of digoxin and xamoterol on arrhythmias in patients with mild to moderate heart failure.
    Klein W; Eber B; Rotman B
    Angiology; 1992 Apr; 43(4):281-6. PubMed ID: 1348403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.
    Sorensen EV; Sterndorff B; Andersen MF; Faergeman O
    Cardiovasc Drugs Ther; 1989 Apr; 3(2):203-9. PubMed ID: 2577283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.
    Lancet; 1988 Mar; 1(8584):489-93. PubMed ID: 2893916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of xamoterol and digoxin in patients with mild to moderate heart failure. The Italian Xamoterol Multicenter Research Group.
    Eur Heart J; 1990 Apr; 11 Suppl A():50-1. PubMed ID: 1971591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.
    Ang EL; Chan WL; Cleland JG; Moore D; Krikler SJ; Alexander ND; Oakley CM
    Br Heart J; 1990 Oct; 64(4):256-60. PubMed ID: 1977430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xamoterol versus digoxin in heart failure.
    Lancet; 1988 Apr; 1(8590):877. PubMed ID: 2895376
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.
    McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG
    Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.
    Waller DG; Webster J; Sykes CA; Bhalla KK; Wray R
    Eur Heart J; 1989 Nov; 10(11):1003-10. PubMed ID: 2574108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    J Cardiol; 1990; 20(3):755-65. PubMed ID: 2151866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.
    Sørensen EV; Faergeman O; Day MA; Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):86S-88S. PubMed ID: 2572265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.